Assessment of various topical oral formulations by bone marrow transplant recipients

被引:9
作者
Bellm, LA
Epstein, JB
Rose-Ped, AM
Fu, R
Martin, PJ
Fuchs, HJ [1 ]
机构
[1] IntraBiot Pharmaceut Inc, Mt View, CA 94043 USA
[2] Univ British Columbia, Vancouver Hosp, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada
[4] Univ Washington, Seattle, WA 98195 USA
[5] Empirica Inc, Portland, OR USA
[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源
ORAL ONCOLOGY | 2001年 / 37卷 / 01期
关键词
marrow transplantation; mucositis; compliance; drug formulations;
D O I
10.1016/S1368-8375(00)00054-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Topical approaches to management of oral mucositis have the advantages of high local concentration and limited or no systemic absorption, reducing the risk of systemic complications. The acceptability of topical therapies in cancer patients has not been evaluated. Thirty-eight transplant patients assessed the acceptability of three formulations (rinse, thin gel, thick gel) of a new compound developed to prevent oral mucositis. The rinse nas selected as the most acceptable formulation. The thick eel received the lowest rating. Consistency was a major determinant of overall acceptability. A neutral taste was desirable for most participants. Room temperature of the formulation was rated as completely acceptable. Most participants would be willing to use the rinse or thin gel several times per day, to retain each dose in the oral cavity for up to 5 min, and to swallow it. The support of caregivers may be needed to achieve compliance with such regimens. (C) 2001 Published by Elsevier Science Ltd.
引用
收藏
页码:42 / 49
页数:8
相关论文
共 8 条
[1]  
Bellm LA, 2000, SUPPORT CARE CANCER, V8, P33
[2]   PATIENT COMPLIANCE WITH ONCE-DAILY AND TWICE-DAILY ORAL FORMULATIONS OF 5-ISOSORBIDE MONONITRATE - A COMPARATIVE-STUDY [J].
BRUN, J .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1994, 22 (05) :266-272
[3]   COMPARISON OF SPRINKLE VERSUS SYRUP FORMULATIONS OF VALPROATE FOR BIOAVAILABILITY, TOLERANCE, AND PREFERENCE [J].
CLOYD, JC ;
KRIEL, RL ;
JONESSAETE, CM ;
ONG, BY ;
JANCIK, JT ;
REMMEL, RP .
JOURNAL OF PEDIATRICS, 1992, 120 (04) :634-638
[4]   Oral cavity complications of bone marrow transplantation [J].
Eisen, D ;
Essell, J ;
Broun, ER .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 1997, 16 (04) :265-272
[5]  
Epstein J B, 1992, Spec Care Dentist, V12, P21, DOI 10.1111/j.1754-4505.1992.tb00401.x
[6]   Oropharyngeal candidiasis: A review of its clinical spectrum and current therapies [J].
Epstein, JB ;
Polsky, B .
CLINICAL THERAPEUTICS, 1998, 20 (01) :40-57
[7]   ANTIFUNGAL THERAPY IN OROPHARYNGEAL MYCOTIC INFECTIONS [J].
EPSTEIN, JB .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 1990, 69 (01) :32-41
[8]   Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: A randomized, crossover trial [J].
McCrindle, BW ;
ONeill, MB ;
CullenDean, G ;
Helden, E .
JOURNAL OF PEDIATRICS, 1997, 130 (02) :266-273